EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Construction of a globally modular recombinant Saccharomyces cerevisiae chassis for ginkgolide precursor levopimaradiene production

De Liu, Ziqing Chen, Zizheng Guo, Qihang Xue, Qiulin He, Rongmin Yu, Jianhua Zhu

Synthetic and Systems Biotechnology · 2026-09 · 13 · 154-162

DOI: 10.1016/j.synbio.2026.01.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Synthetic and Systems Biotechnology, 2026-09. Verfasst von De Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou, 511443, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The production of biologically active natural products through microbial metabolic factories, such as Saccharomyces cerevisiae , represents a promising approach to achieving green and sustainable production. However, establishing a stable metabolic flux for natural products by disrupting the natural evolutionary pathways of S. cerevisiae remains a significant challenge. This phenomenon is often associated with strain growth stagnation, presenting a key bottleneck in metabolic engineering. Here, we successfully devised a recombinant S. cerevisiae chassis strain capable of producing levopimaradiene (LP), a critical precursor for ginkgolide biosynthesis. By systematically modifying levopimaradiene synthase (LPS), modulating the mevalonate pathway, and enhancing the supply of acetyl-coenzyme A, ATP, and NADPH, we significantly improved the titer of LP. Shake flask fermentation achieved a LP titer of 792.72 ± 69.59 mg/L, while fed-batch fermentation further elevated the titer to 1809.32 ± 72.32 mg/L. This represents a 8.3-fold increase over the previously reported S. cerevisiae chassis strain, corresponding to the highest titer reported to date. This study provides a strategy for the construction of ginkgolide chassis factories. Moreover, it offers a conceptual framework for the construction of factories for the production of diterpene, with a particular focus on the field of S. cerevisiae production.

Schlagwörter

Stichwörter der Autor:innen

Geranylgeranyl diphosphateGinkgolideLevopimaradieneMetabolic engineering

Autor:innen und Institutionen

  • Biotechnological Institute of Chinese Materia Medica, Jinan University, Guangzhou, 511443, China.
  • Department of Natural Product Chemistry, Jinan University, Guangzhou, 511443, China.

Förderung

  • National Natural Science Foundation of China
  • Guangdong Provincial Natural Science Foundation

Zitieren

APA

Liu, Chen, Z., Guo, Z., Xue, Q., He, Q., Yu, R., & Zhu, J. (2026). Construction of a globally modular recombinant Saccharomyces cerevisiae chassis for ginkgolide precursor levopimaradiene production. Synthetic and Systems Biotechnology, 13, 154-162. https://doi.org/10.1016/j.synbio.2026.01.018

Vancouver

Liu, Chen Z, Guo Z, Xue Q, He Q, Yu R, et al. Construction of a globally modular recombinant Saccharomyces cerevisiae chassis for ginkgolide precursor levopimaradiene production. Synthetic and Systems Biotechnology. 2026;13:154-162. doi:10.1016/j.synbio.2026.01.018

BibTeX
@article{Liu2026,
  author = {Liu, De and Chen, Ziqing and Guo, Zizheng and Xue, Qihang and He, Qiulin and Yu, Rongmin and Zhu, Jianhua},
  title = {Construction of a globally modular recombinant Saccharomyces cerevisiae chassis for ginkgolide precursor levopimaradiene production},
  journal = {Synthetic and Systems Biotechnology},
  year = {2026},
  volume = {13},
  pages = {154--162},
  doi = {10.1016/j.synbio.2026.01.018}
}
Kostenlos starten →